

**Table S1. Summary of demographic and clinical data of patients included for vascular SET7/9 level analysis.**

	Control group (n=10)	ESRD group (n=20)
Male (%)	80.00	73.33
Age (year)	55.20±7.45	54.03±15.61
BMI (kg/m <sup>2</sup> )	22.68±6.06	22.49±3.25
Hypertension (%)	90.00	90.00
Diabetes (%)	50.00	33.33
MAP (mmHg)	89.67±7.81	94.83±9.40
eGFR (mL/min/ 1.73m <sup>2</sup> )	77.50 (IQR 58.50-90.00)	7.00 (IQR 4.65-9.00)*
BG (mmol/L)	5.73±1.44	5.87±0.78
TC (mmol/L)	3.68±0.68	4.51±1.36
TG (mmol/L)	1.37±0.40	1.94±1.05
Ca (mmol/L)	1.96±0.08	1.98±0.10
P (mmol/L)	0.93±0.20	2.07±0.74*

ESRD, end-stage renal disease; BMI, body mass index; MAP, mean artery pressure;

eGFR, estimated glomerular filtration rate; BG, blood glucose; TC, total cholesterol;

TG, triglyceride; Ca, calcium; P, phosphate.

Compared with control group, \*P<0.001.

**Table S2 The antibodies for Western blot.**

<b>Protein</b>	<b>Antibody</b>	<b>Source</b>	<b>Dilution</b>	<b>Molecular weights(kD)</b>
<b>Beclin1</b>	Mouse monoclonal to Beclin1	Abcam, Cambridge, MA, USA	1:1000	50
<b>Runx2</b>	Mouse monoclonal to Runx2	Abcam, Cambridge, MA, USA	1:1000	68
<b>SET7/9</b>	Rabbit polyclonal to SET7/9	Abcam, Cambridge, MA, USA	1:1000	50
<b>P62</b>	Rabbit monoclonal to P62	Cell signaling technology, Danvers, MA, USA	1:1000	60
<b>GAPDH</b>	Mouse monoclonal to GAPDH	Abcam, Cambridge, MA, USA	1:1000	38